Guo Meng-Qi, Luo Xing-Yu, Wu Hui-Yang, Huang Yu-Xian
Department of Hematology, Zhu Jiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China.
Department of Hematology, Zhu Jiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China,E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2022 Oct;30(5):1622-1626. doi: 10.19746/j.cnki.issn.1009-2137.2022.05.051.
Abnormal cell apoptosis is closely related to the occurrence of hematologic tumors, B-cell lymphoma-2 (BCL-2), as a key anti-apoptotic protein in intrinsic programmed cell death, has become a hot spot in the treatment of hematologic tumors in recent years. Venetoclax is an oral small-molecule selective BCL-2 inhibitor approved by the Food and Drug Administration (FDA） for the treatment of chronic lymphocytic leukemia (CLL) patients or small lymphocytic lymphoma (SLL) patients and for the treatment of elderly acute myeloid leukemia (AML) patients that is not suitable for aggressive chemotherapy. In addition, it also showed a promising clinical application in treatment of non-Hodgkin's lymphoma (NHL) patients, which is a new expansion of the clinical indications for venetoclax. In this review, the role of BCL-2 protein family played in the regulation of NHL cell apoptosis, the development of BCL-2 inhibitors and the recent research progress of venetoclax in the treatment of NHL are reviewed.
异常细胞凋亡与血液系统肿瘤的发生密切相关，作为内源性程序性细胞死亡中的关键抗凋亡蛋白，B细胞淋巴瘤-2（BCL-2）近年来已成为血液系统肿瘤治疗的热点。维奈克拉是一种口服小分子选择性BCL-2抑制剂，已获美国食品药品监督管理局（FDA）批准，用于治疗慢性淋巴细胞白血病（CLL）患者或小淋巴细胞淋巴瘤（SLL）患者，以及不适于进行强化化疗的老年急性髓系白血病（AML）患者。此外，它在治疗非霍奇金淋巴瘤（NHL）患者方面也显示出有前景的临床应用，这是维奈克拉临床适应证的新扩展。在本综述中，将对BCL-2蛋白家族在NHL细胞凋亡调控中的作用、BCL-2抑制剂的研发以及维奈克拉治疗NHL的最新研究进展进行综述。
